down arrow

Adicet Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0070021086
USD
0.52
0.03 (5.57%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.490.52

52 Week

0.451.11
Valuation
Technical
Day's Volume

CASH

1.39 M

Shareholding (Mar 2025)

FII

8.28%

Held by 52 FIIs

DII

59.49%

Held by 20 DIIs

Promoter

19.33%

How big is Adicet Bio, Inc.?

22-Jun-2025

As of Jun 18, Adicet Bio, Inc. has a market capitalization of 55.61 million and reported net sales of 0.00 million, with a net profit of -117.32 million over the latest four quarters. Shareholder's funds are 186.61 million, and total assets amount to 220.22 million.

As of Jun 18, Adicet Bio, Inc. has a market capitalization of 55.61 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters. Additionally, the sum of net profit for the same period was -117.32 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 186.61 million and total assets amounting to 220.22 million.

Read More

What does Adicet Bio, Inc. do?

22-Jun-2025

Adicet Bio, Inc. is a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, classified as a micro-cap with a market cap of $55.61 million. As of March 2025, it reported a net profit loss of $28 million and has no dividend yield.

Overview:<BR>Adicet Bio, Inc. is a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -28 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 55.61 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.91 <BR>Return on Equity: -72.67% <BR>Price to Book: 0.34<BR><BR>Contact Details:<BR>Address: 500 Boylston St Fl 12, BOSTON MA: 02116-3740 <BR>Tel: 1 617 4822333 <BR>Fax: 1 302 6555049 <BR>Website: https://www.adicetbio.com/

Read More

Who are in the management team of Adicet Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Adicet Bio, Inc. is led by Mr. Chen Schor as President and CEO, with a Board of Directors that includes Mr. Erez Chimovits, Mr. Steve Dubin, Mr. Carl Gordon, Dr. Aya Jakobovits, and Dr. Bastiano Sanna.

As of March 2022, the management team of Adicet Bio, Inc. includes Mr. Chen Schor, who serves as the President, Chief Executive Officer, Secretary, and Director. Additionally, the Board of Directors consists of Mr. Erez Chimovits, Mr. Steve Dubin, Mr. Carl Gordon, Dr. Aya Jakobovits, and Dr. Bastiano Sanna, all of whom hold the designation of Director.

Read More

Is Adicet Bio, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2023, Adicet Bio, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics such as a -72.67% return on equity and a year-to-date stock performance of -34.01%, significantly underperforming its peers and the S&P 500.

As of 9 May 2023, the valuation grade for Adicet Bio, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, as evidenced by its price-to-book value of 0.39 and an EV to EBITDA ratio of 0.71, which are not favorable compared to its peers. Notably, Adicet's return on equity (ROE) stands at a concerning -72.67%, highlighting the challenges it faces in generating returns for shareholders.<BR><BR>In comparison to its peers, such as ADC Therapeutics SA, which is rated risky with an EV to EBITDA of -4.8904, and Kinnate Biopharma, Inc., which is rated fair with an EV to EBITDA of 0.2381, Adicet's metrics suggest it is lagging behind in terms of financial health. The company's recent stock performance has also been poor, with a year-to-date return of -34.01%, significantly underperforming the S&P 500's 2.44% return. This combination of unfavorable ratios and weak market performance reinforces the conclusion that Adicet Bio, Inc. is overvalued at its current price of 0.63.

Read More

Is Adicet Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Adicet Bio, Inc. is in a mildly bearish trend, indicated by daily moving averages and monthly Bollinger Bands, with a significant 1-year return of -44.49% compared to the S&P 500's 17.14%.

As of 12 September 2025, the technical trend for Adicet Bio, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and monthly Bollinger Bands showing a mildly bearish trend. Although the weekly MACD is mildly bullish, the overall indicators suggest weakness. The stock has underperformed significantly compared to the S&P 500, with a 1-year return of -44.49% versus the S&P 500's 17.14%, reflecting a challenging environment for the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 64 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-88.95%

stock-summary
Price to Book

0.48

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-31 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-37.47%
0%
-37.47%
6 Months
-18.21%
0%
-18.21%
1 Year
-41.9%
0%
-41.9%
2 Years
-68.34%
0%
-68.34%
3 Years
-93.45%
0%
-93.45%
4 Years
-96.74%
0%
-96.74%
5 Years
-96.37%
0%
-96.37%

Adicet Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-33.37%
EBIT to Interest (avg)
-87.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
91.24%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.39
EV to EBIT
0.67
EV to EBITDA
0.71
EV to Capital Employed
-6.06
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-72.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 28 Schemes (12.9%)

Foreign Institutions

Held by 52 Foreign Institutions (8.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -10.64% vs 1.74% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.80",
          "val2": "-28.20",
          "chgp": "-9.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.20",
          "val2": "-28.20",
          "chgp": "-10.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.94% vs -104.44% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-121.10",
          "val2": "-126.50",
          "chgp": "4.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-19.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-117.10",
          "val2": "-142.70",
          "chgp": "17.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-30.80
-28.20
-9.22%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-31.20
-28.20
-10.64%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -10.64% vs 1.74% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-121.10
-126.50
4.27%
Interest
0.00
0.00
Exceptional Items
0.00
-19.50
100.00%
Consolidate Net Profit
-117.10
-142.70
17.94%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.94% vs -104.44% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Adicet Bio, Inc. stock-summary
stock-summary
Adicet Bio, Inc.
Pharmaceuticals & Biotechnology
Adicet Bio Inc., formerly resTORbio, Inc., is a biotechnology company. The Company is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.
Company Coordinates stock-summary
Company Details
500 Boylston St Fl 12 , BOSTON MA : 02116-3740
stock-summary
Tel: 1 617 4822333
stock-summary
https://www.adicetbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."